- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02371681
NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis
Background:
- Tuberculosis (TB) is a lung infection caused by bacteria. When people with TB cough, they may spread these bacteria. Researchers are looking for new TB medicines. They want to find a faster way to tell if a drug might combat TB.
Objective:
- To learn the effect of different anti-TB drugs on microbiological, radiographic and immunologic markers in people with TB.
Eligibility:
- Adults age 18-65 who weigh 30-90 kg and have common TB bacteria that can be treated with common TB medicines.
Design:
- Participants will be admitted to the hospital for screening. They will have medical history, physical exam, and chest radiograph. They will give blood, urine, and sputum samples.
- Participants will be put in 1 of 8 groups.
- Participants will get one or a combination of TB medicines daily for about 14 days.
- Each day, participants:
- Will discuss side effects.
- May have a physical exam.
- Will spit mucus into a cup. They may breathe in saline water through a nebulizer to make them cough.
- Participants will have blood taken 3-4 times during the study
- Participants will have 2-3 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) scans. FDG is a radioactive sugar molecule which helps measure TB disease in the lungs. It will be injected into a vein. Participants will lie in a scanner that takes pictures.
- Around study day 14, participants will leave the hospital. They will be referred to a local TB clinic. There they will get the standard 4 TB medicines. Those in group 8 will already be on these medicines and will have another FDG-PET/CT on day 28.
- Participants will be in the study for up to 28 days.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Early bactericidal activity (EBA), which measures decline in serial sputum colony forming unit (CFU) counts over the first 2-14 days of treatment, has been used extensively as a means of initially evaluating the potency of individual or combinations of antituberculous agents. This approach is endorsed by the Global Alliance for TB Drug Development and the US FDA. However, EBA seems to correlate poorly with the relative ability of an agent to prevent relapse and produce a durable cure (often referred to as sterilizing activity ). The reasons for this discrepancy may have to do with a limitation of sputum measurements to capture populations that persist beyond airway surfaces in discrete lesions such as granulomas, nodules, or cavities. The elimination of these persistent populations depend on the pharmacodynamic properties of a regimen and may be better captured by biologic and functional markers that can reflect dynamic treatment effects within these relevant host environments.
Recent studies of the response to TB chemotherapy have identified promising new biomarkers of sterilization in 2 areas. First, immunologic changes appear to have potential in small subject cohorts to predict sterilizing cure within 1 month after commencing treatment. Second, 18F-FDG PET/CT has been used in tuberculosis as a qualitative means of assessing drug response in small case series at multiple time points, starting as early as 1 month. PET activity reflects uptake and phosphorylation of FDG by neutrophils and macrophages, and CT provides structural information on disease pathology. Hence, PET/CT data may offer additional insights into lesion-specific sterilizing activity. This study will add 18F-FDG PET/CT scans and immunological assays at 0, 2, and (in the HRZE arm) 4 weeks to standard EBA methodology using regimens containing isoniazid (INH [H]), rifampin (RIF [R]), pyrazinamide (PZA [Z]), moxifloxacin (MXF [M]), and ethambutol (EMB [E]). We hypothesize that drug regimens associated with higher sterilizing activity (e.g., containing rifampin or pyrazinamide) will show distinctive early cytokine and chemokine patterns and discrete, quantifiable changes on PET/CT in certain lesion types during the 2-week period, compared to drug regimens with poor sterilizing activity (e.g., containing isoniazid or moxifloxacin). Demonstration of such an association would provide rationale for including radiologic and immunologic analysis, alongside conventional EBA, in early phase clinical studies of novel drugs, and would also provide important new insights into the biology of human and bacterial responses to TB drugs.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cape Town, South Africa
- Stellenbosch University, Faculty of Medicine and Health Sciences
-
Cape Town, South Africa
- TASK Applied Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA:
- Age 18 to 65 years with body weight from 30 kg to 90 kg
- Sputum acid-fast bacilli (AFB) smear positive (at least 1+ on the WHO International Union Against Tuberculosis and Lung Disease scale)
- Likely able to produce approximately 10 mL of sputum per day
- Xpert MTB/RIF-confirmed M.tb
- Rifampin-sensitive pulmonary tuberculosis as indicated by Xpert MTB/RIF
- ALT <3X upper limit of normal, creatinine <2X upper limit of normal
- Willingness to have samples stored
EXCLUSION CRITERIA:
- Clinically suspected disseminated TB or acuity of illness too much as deemed by clinicians
- Has been treated for tuberculosis within the past 3 years
- Treatment with agents known to have anti-tuberculosis activity (e.g., fluoroquinolones, linezolid) for any indications during the current episode of clinical illness or within 2 months prior to screening, whichever is longer
- Cirrhosis or chronic kidney disease
- Disease complications or concomitant illness that might compromise safety or the interpretation of trial endpoints, such as known diagnosis of chronic inflammatory condition (e.g., sarcoidosis, rheumatoid arthritis, and connective tissue disorder)
- Use of immunosuppressive medications, such as TNF-alpha inhibitors or systemic or inhaled corticosteroids, within 2 weeks prior to screening
- Subjects with diabetes, point of care HbA1c above 6.5, or random glucose over 200 mg/dL
- Conditions which compromise the subject s ability to take or absorb oral drugs
- Normal PA-Chest radiograph, determined during screening
- Total lung (left or right) collapse on PA-Chest radiograph
- HIV positive
- Pregnant or breastfeeding
- Any other condition that, in the responsible clinician s judgment, renders a subject too sick to safely tolerate 2 weeks study therapy
- Any condition that constitutes a contraindication to any of the drugs to be used on any study arms
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
TB drugs
|
Different Drug combinations
PET/CT Scans
Sample Collection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To characterize, in the context of a standard EBA study, the effect of various antituberculosis drugs on radiographic and immunologic markers as measured by PET/CT and immunologic assays, in subjects with drug sensitive pulmonary tuberculosis wh...
Time Frame: 14 days
|
A description of the individual markers that change over time is of interest to better understand both the markers and the effects of each treatment.
A second analysis will focus on classification of whether a treatment arm includes: 1) only one agent ( singlet ), 2) only two agents (a doublet ), or 3) four agents (a quadruplet ).
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PET/CT Changes
Time Frame: 14 days
|
Correlation of PET/CT changes with treatment response, microbiologic and immunologic outcomes
|
14 days
|
Rank order of drugs
Time Frame: 14 days
|
Comparison of the rank order of drugs based upon bacteriologic, radiologic and immunologic features.
|
14 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Clifton E Barry, Ph.D., National Institute of Allergy and Infectious Diseases (NIAID)
Publications and helpful links
General Publications
- Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol. 2010 May;5(2):96-114. doi: 10.2174/157488410791110797.
- Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology. 2000 Jul;216(1):117-21. doi: 10.1148/radiology.216.1.r00jl19117.
- Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med. 2003 May 15;167(10):1348-54. doi: 10.1164/rccm.200210-1125OC. Epub 2003 Jan 6.
- Jones A, Saini J, Kriel B, Via LE, Cai Y, Allies D, Hanna D, Hermann D, Loxton AG, Walzl G, Diacon AH, Romero K, Higashiyama R, Liu Y, Berg A. Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts. BMC Infect Dis. 2022 Apr 2;22(1):327. doi: 10.1186/s12879-022-07308-3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999915070
- 15-I-N070
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Tuberculosis
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Tjip van der WerfGadjah Mada University; The Enose Company, Zutphen the NetherlandsCompletedPulmonary Tuberculosis Suspected | Other Specified Chronic Obstructive Pulmonary Disease | Pulmonary Tuberculosis TB (+) Histology, (-) BacteriologyIndonesia
-
Research Institute of Epidemiology, Microbiology...Active, not recruitingAspergillosis | Pulmonary Tuberculoses | Old Tuberculosis | Active Tuberculosis | Chronic Pulmonary AspergillosisUzbekistan
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University of Liverpool; Ministry... and other collaboratorsRecruitingMulti-drug Resistant Tuberculosis | Pulmonary Tuberculoses | Extensively Drug-Resistant TuberculosisBelarus, South Africa, Uzbekistan
-
Radboud University Medical CenterEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Department... and other collaboratorsCompletedPulmonary Tuberculosis (TB)South Africa
-
National Institute of Allergy and Infectious Diseases...International Tuberculosis Research CenterWithdrawnRefractory Pulmonary TuberculosisKorea, Republic of
-
Assiut UniversityUnknownExtra Pulmonary Tuberculosis
-
Karolinska InstitutetAddis Ababa University; Armauer Hansen Research Institute, EthiopiaCompleted
-
Michael HoelscherRadboud University Medical Center; German Federal Ministry of Education and... and other collaboratorsCompletedPulmonary Tuberculoses | Other Specified Pulmonary TuberculosisSouth Africa
Clinical Trials on Treatment
-
PfizerCompleted
-
PfizerCompleted
-
Chiesi Farmaceutici S.p.A.Completed
-
Gilead SciencesCompletedChronic Lymphocytic LeukemiaUnited States
-
JW PharmaceuticalCompletedHealthyKorea, Republic of
-
PfizerCompleted
-
AstraZenecaParexelCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingIntra-articular Fracture of the Mandibular CondyleFrance
-
PfizerCompletedHealthy VolunteersUnited States
-
New Mexico VA Healthcare SystemCompletedPost Traumatic Stress DisorderUnited States